脑肠轴

Search documents
专家热议《Nature》:王卫庆/王计秋团队解密“脑肠轴”掌控体重
GLP1减重宝典· 2025-09-30 03:02
以下文章来源于肥胖世界ObesityWorld ,作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展,为医学减重临床、教研人员搭建一座与国际接轨的桥梁,「每医健」旗下内容平台。 在脊椎动物体内,脑干的迷走神经运动背核(DMV)掌管着胸腔和腹腔器官的副交感神经活动,如呼吸、心跳和肠道蠕动等。那么,除了调 控肠道运动、感觉和腺体分泌外,迷走神经是否还能直接影响营养物质的吸收?这个问题极具吸引力。由于DMV位于脑干,是大脑与肠道之 间的关键枢纽,研究人员认为这里可能隐藏着解答这一问题的突破点。 在脑干区域,Phox2b基因会特异性表达在迷走神经复合体的DMV和孤束核(NTS)中。利用Phox2b-cre小鼠和药物遗传学工具,科学家首先 抑制了Phox2bDMV神经元的活性,结果发现高脂饮食导致肥胖的小鼠出现了血脂和体重的显著下降,原因在于肠道对油脂的吸收减少,而粪 便中的油脂排泄增多。为排除Phox2bNTS神经元的影响,团队又用DMV高表达的Chat-cre小鼠进行了验证,进一步确认了大脑中枢可以调控 肠道油脂吸收这一全新生理现象。 众 ...
重磅!中国团队登《自然》:王卫庆/王计秋揭秘"脑肠黄金通道"操控体重密码
GLP1减重宝典· 2025-09-07 09:49
以下文章来源于肥胖世界ObesityWorld ,作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展,为医学减重临床、教研人员搭建一座与国际接轨的桥梁,「每医健」旗下内容平台。 众所周知,高脂饮食会诱发肥胖,而增加油脂排出有助于减肥。为探索这一发现的临床转化前景,研究团队筛选了多种化合物,最终发现中药 单体葛根素能显著降低Phox2bDMV神经元的电活动频率,从而抑制神经元活性。葛根素能够穿越血脑屏障,研究人员通过腹腔注射葛根素, 发现其确实能够促进油脂排出、帮助减重。进一步采用脑室注射实验,证实葛根素的中枢作用部位。 虽然临床上葛根素注射液被用于治疗心血管疾病,但其具体靶点和作用机制一直不明。该研究团队在寻找葛根素分子靶点过程中,利用生物素 标记的葛根素探针和"点击化学(光交联)"技术,将探针与脑干样本孵育,并通过蛋白质质谱筛选出500多个潜在结合蛋白。结合葛根素的电 生理特性和Allen Brain Atlas数据库表达谱,最终锁定了GABRA1蛋白为关键结合对象,并通过冷探针竞争实验加以验证。值得注意的是, GABRA1在DM ...
北大天才韦东奕健康问题背后,揭露了绝大数人的问题
3 6 Ke· 2025-06-16 02:34
Core Viewpoint - The health issues faced by mathematician Wei Dongyi highlight the nutritional challenges faced by busy professionals, particularly entrepreneurs, emphasizing the importance of systematic health management in daily life [2][3]. Group 1: Health Challenges - Wei's health problems, particularly periodontitis, have drawn attention to the nutritional imbalances prevalent among busy individuals [3]. - His dietary habits reveal a preference for refined carbohydrates, with minimal intake of proteins, fruits, and vegetables, leading to potential nutritional deficiencies [4][5]. - The lack of essential nutrients, such as protein and vitamins, may contribute to his deteriorating health and increased risk of conditions like periodontitis [6][7][8]. Group 2: Nutritional Insights - Long-term nutritional deficiencies can accelerate aging and weaken the immune system, as seen in Wei's physical decline [11]. - A diet high in refined carbohydrates and low in proteins and fats can lead to poor skin health and emotional instability [12][13]. - Regular health check-ups may overlook early signs of nutritional deficiencies, which can have broader health implications [14][15]. Group 3: Recommendations for Entrepreneurs - Busy professionals should prioritize high-nutrition, low-calorie foods to combat the negative health impacts of fast-paced lifestyles [18][19]. - Carrying healthy snacks can provide quick nutrition and prevent reliance on unhealthy food options [24][25]. - Avoiding excessive reliance on takeout and refined carbohydrates is crucial for maintaining cognitive function and overall health [27][28][30]. Group 4: Emotional and Mental Health - Nutritional deficiencies can lead to emotional fluctuations, with specific vitamins and minerals playing key roles in mood regulation [33][34][35]. - Maintaining a balanced intake of fats, particularly Omega-3, is essential for mental health and emotional stability [36][37]. Group 5: Holistic Health Management - A balanced approach to eating, sleeping, and physical activity is vital for overall health [39]. - Regular sleep patterns and physical activity can significantly impact weight management and overall well-being [46][49]. - The importance of hydration and nutrient-dense foods cannot be overstated in maintaining energy levels and health [60].
绿谷医药回应“国产阿尔茨海默病新药断货”!药品注册证到期
Nan Fang Du Shi Bao· 2025-06-12 09:32
Core Viewpoint - The first domestic Alzheimer's disease drug, Ganluotena Capsules (brand name: Jiuqi Yi), is facing a supply shortage due to production halts related to its registration certificate expiration, but the company, Shanghai Green Valley Pharmaceutical Technology, is in the final stages of approval and is optimistic about resuming supply soon [1][2]. Group 1: Product and Market Information - Ganluotena Capsules are priced over 1,000 yuan per box online, with a specification of 150mg and 42 capsules per box, requiring patients to take 6 capsules daily [1]. - The drug was conditionally approved by the National Medical Products Administration (NMPA) in November 2019 and was included in the medical insurance directory at the end of 2021, with the price reduced from 895 yuan to 296 yuan per box [1]. - Since its launch, over 500,000 patients have used Ganluotena, with sales exceeding 2.1 million boxes in 2024 alone [5]. Group 2: Regulatory and Production Status - The production halt is temporary and limited to the Ganluotena product line due to the need for a new registration certificate, with employees receiving minimum wage during this period [2]. - The company submitted supplementary applications for Ganluotena in May and October 2024, which will undergo comprehensive evaluation by the drug review center [3]. Group 3: Scientific and Clinical Background - Ganluotena is the world's first drug targeting the gut-brain axis for Alzheimer's disease, aiming to reshape gut microbiota, inhibit neuroinflammation, and improve cognitive function [4]. - The drug has faced controversy regarding its mechanism and the authenticity of research papers by its main inventor, but legal challenges against these criticisms have been dismissed [4].
绿谷医药停产阿尔茨海默病治疗药物 三重质疑下的破冰者终陷困局
Xin Lang Zheng Quan· 2025-06-11 01:12
Core Insights - The Chinese original drug "Jiuyiqi®" (Guanluo Sodium) has been discontinued after five years, marking a significant event in the Alzheimer's disease (AD) drug market [1][2] - Initially approved in November 2019, Jiuyiqi® was celebrated as the first targeted AD drug, but faced ongoing scrutiny regarding its safety and efficacy [1][2] Group 1: Drug Approval and Market Performance - Jiuyiqi® received "conditional approval" from the National Medical Products Administration, which required further submission of carcinogenicity test reports and long-term efficacy data [1] - The drug experienced a surge in demand upon its market entry and was included in the national medical insurance directory in 2021, expanding its market presence [2] - However, following the termination of international trials and internal team instability, sales declined sharply, leading to reports of stock shortages in pharmacies [2] Group 2: Controversies and Challenges - The drug's unique "gut-brain axis" mechanism faced strong criticism from the academic community, raising questions about its scientific validity [1] - Controversies arose from the clinical trial results, where the treatment group showed effects within four weeks, while the placebo group unexpectedly worsened, leading to debates over trial design [1] - The international Phase III trial, originally set to complete in 2025, was prematurely terminated in 2022, attributed to patient dropouts due to the pandemic and financing difficulties, which did not alleviate concerns over data reliability [1][2] Group 3: Regulatory and Industry Implications - The discontinuation of Jiuyiqi® serves as a warning for the Chinese innovative drug sector, highlighting the risks associated with "conditional approval" [2] - The situation raises questions about the regulatory environment and whether the approval process is becoming more stringent, as the company did not publicly address the reasons for the discontinuation [2] - The industry is urged to recognize that significant original mechanisms must withstand rigorous scrutiny from international peers, and academic criticism should be viewed as an opportunity to enhance research quality [2]